PRODUCT INFORMATION



Bindarit

Item No. 11479

CAS Registry No.: 130641-38-2

Formal Name: 2-methyl-2-[[1-(phenylmethyl)-1H-

indazol-3-yl]methoxy]-propanoic acid

Synonym: MF: $C_{19}H_{20}N_2O_3$ FW: 324.4 **Purity:**

UV/Vis.: Supplied as: A crystalline solid

Storage: -20°C Stability: ≥2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

Bindarit is supplied as a crystalline solid. A stock solution may be made by dissolving the bindarit in the solvent of choice. Bindarit is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of bindarit in ethanol is approximately 20 mg/ml and approximately 30 mg/ml in DMSO and DMF.

Bindarit is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, bindarit should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Bindarit has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Bindarit is an inhibitor of monocyte chemoattractant protein (MCP) production that is selective for MCP-1/CCL2, MPC-3/CCL7, and MCP-2/CCL8 over other chemokines. It inhibits LPS- or C. albicansinduced production of MCP-1/CCL2 in isolated human monocytes (IC_{50} s = 172 and 403 μ M, respectively).² Bindarit downregulates NF-κB signaling and prevents p65 and p65/p50-mediated MCP-1/CCL2 promoter activation in RAW264.7 cells.³ It delays the onset of proteinuria and prolongs survival in a mouse model of experimental lupus nephritis when administered at a dose of 50 mg/kg.4 It prevents LPS-induced increases in MCP-1/CCL2 expression in mouse brain and spinal cord when administered at a dose of 200 mg/kg and reduces the incidence and severity of experimental autoimmune encephalomyelitis (EAE) in mice.⁵ Bindarit is also a noncompetitive inhibitor of monocarboxylate transporter 4 (MCT4; K_i = 30.2 μM for the human transporter) that is selective for MCT4 over MCT1.6

References

- 1. Mirolo, M., Fabbri, M., Sironi, M., et al. Eur. Cytokine. Netw. 19(3), 119-122 (2008).
- 2. Sironi, M., Guglielmotti, A., Polentarutti, N., et al. Eur. Cytokine. Netw. 10(3), 437-442 (1999).
- 3. Mora, E., Guglielmotti, A., Biondi, G., et al. Cell Cycle 11(1), 159-169 (2016).
- 4. Zoja, C., Corna, D., Benedetti, G., et al. Kidney Int. 53(3), 726-734 (1998).
- 5. Ge, S., Shrestha, B., Paul, D., et al. J. Neuroinflammation 9,171, (2012).
- Futagi, Y., Kobayashi, M., Narumi, K., et al. Biochem. Biophys. Res. Commun. 495(1), 427-432 (2018).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/01/2019

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA **PHONE:** [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM